Johnson & Johnson is to press on with filings for its new depression drug, esketamine, despite one of two late-stage studies missing an efficacy target. Ketamine is best known as an anaesthetic ...

Janssen’s potential depression treatment made from esketamine – a version of the substance notoriously used illegally as a party drug – is to be reviewed by advisers to the FDA at a crunch ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD). TRD is defined ...

Esketamine Market: Revolutionizing Treatment-Resistant Depression The esketamine market is experiencing significant growth, driven by the urgent need for effective treatments for treatment ...